Q3 2024 PTC Therapeutics Inc Earnings Call Transcript
Key Points
- PTC Therapeutics Inc (PTCT) achieved total revenue of $197 million in the third quarter, with $124 million from the DMD franchise.
- The company closed the quarter with over $1 billion in cash and raised its 2024 total revenue guidance to $750 million to $800 million.
- PTC Therapeutics Inc (PTCT) submitted two NDAs to the FDA for sepiapterin and Translarna, both of which have been accepted for filing.
- The sepiapterin NDA is supported by significant efficacy data from the Phase 3 APHENITY study, and marketing authorization applications are under review in multiple regions.
- The PTC518 program for Huntington's disease received Fast Track Designation from the FDA, indicating potential for accelerated approval.
- PTC Therapeutics Inc (PTCT) faces challenges in the European market due to CHMP's recent negative opinion on Translarna's renewal.
- The FDA has not provided an action date for the Translarna NDA, creating uncertainty in the regulatory timeline.
- The company is experiencing competitive pressures in the US market for Emflaza due to generic competition.
- There is uncertainty regarding the European Commission's decision on Translarna, which could impact revenue from Europe.
- The company is awaiting further feedback from ANVISA regarding the independent assessment of Translarna in Brazil.
Welcome to the PTC third-quarter 2024 financial results conference call. At this time all participants are in a listen-only mode. After the speaker's presentation, there will be a question-and-answer session. (Operator Instructions)
Again please be advised that today's conference is being recorded. I would now like to hand the conference over to your first speaker today, Jane Hanlon, Associate Director of Investor Relations. Please go ahead.
Good afternoon and thank you for joining us today to discuss PTC Therapeutics' third quarter 2024 corporate update and financial results. I am joined today by our Chief Executive Officer, Dr. Matthew Klein; our Chief Business Officer, Eric Pauwels; and our Chief Financial Officer, Pierre Gravier.
Today's call will include forward-looking statements based on our current expectations. Please take a moment to review the slide posted on our investor relations website in conjunction with the call, which contains information about our forward-looking statements.
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
